TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2 to 12 weeks after first ever stroke according to the World Health Organisation criteria (previous transient ischaemic attack or clinically silent infarct on computerised tomography (CT)/magnetic resonance imaging (MRI) are not counted as previous stroke)~* Stroke confirmed by CT/MRI scan and classified as ischaemic/haemorrhagic stroke~* Presence of spasticity:~  * either symptomatic, based on symptomatic spasticity criteria (i.e. at least one of the following items: impacted passive/active function, involuntary movements, or pain ≥4 on a numeric pain rating scale \[NPRS\]), in addition to increased muscle tone \[Modified Ashworth Scale, MAS ≥2\])~ * or only increased muscle tone (MAS≥2)~Exclusion Criteria:~* Neuromuscular junction (NMJ) diseases, or any other neurological disorders (including prior local joint, tendon, and intrinsic muscle disorders) that could potentially interfere with assessment of spasticity in the primary targeted muscle group selected by the Investigator and in agreement with the subject~* Currently receiving drugs affecting NMJ transmission e.g. aminoglycosides, aminoquinolines, cyclosporine, D penicillamine~* Previous surgery of the affected muscles/ ligaments/tendons~* Severe comorbidities (e.g. congestive heart failure, myocardial infarction, multiple organ failure, hepatic renal failures, severe infections)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): Dysport® 500U intramuscular injection
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Anti-IgE in Chronic Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant, non-breastfeeding females~* Chronic urticaria defined as symptoms \>50% of the days or 3 days per week for more than 12 weeks~* History of angioedema~* Chronic daily therapy with anti-histamines and stable doses of antihistamines for at least 4 weeks.~* High baseline score for pruritis (at least 2 on a 3 point scale)~* No other etiology identified for chronic urticaria such as drug-related or physical urticaria as determined by history, physical examination and laboratory studies~Exclusion Criteria:~* Concomitant use of systemic corticosteroids for 1 month prior to enrollment. Topical steroid use will not be permitted, but inhaled topical steroids are allowed.~* Current use of immunosuppressive medication (cyclosporine, IVIg, methotrexate, cyclophosphamide). Any such medication will be discontinued for at least 6 weeks before screening.~* Treatment with any investigational agent within 30 days of screening~* Previous treatment with omalizumab~* Recent history of drug or alcohol abuse (within 3 years prior to study)~* Active atopic dermatitis requiring the use of topical steroid agents~* Clinically relevant cardiovascular, hepatic, neurologic, psychiatric, endocrine, or other major systemic disease making the protocol or interpretation of the study results difficult.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis (using the SCID-I/P at screening visit) of schizophrenia or schizoaffective disorder and judged to be stable (without hospitalization or acute exacerbation and functioning in society) on psychiatric treatment for at least the past 6 month.~* Current cigarette smokers (at least 15/day during the past year with no period of abstinence greater than 3 months in the past year) male or female, between the ages of 18 and 75 inclusive, who are motivated to stop smoking.~* Score 7 or higher on the Contemplation Ladder at the Screening, Week -1, and Baseline Visits.~Exclusion Criteria:~* PANSS score \>70 at Screen or Baseline Visit.~* Subjects hospitalized within the past six months due to suicidal ideation or suicidal behavior or subjects considered to have serious suicidal ideation or suicidal behavior within the past six moth.~* Subjects having active suicidal ideation or behavior identified at Screen, Week -1, or Baseline Visit.~* Subjects taking Bupropion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): Randomization 2:1 treatment to placebo
- Treatment Arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Corneal Densitometry Changes With Adenoviral SEI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adenoviral SEI~Exclusion Criteria:~* Other corneal diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- Tacrolimus (Type: None): Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
- Phototherapeutic Keratectomy (Type: None): Patients underwent transepithelial PTK for subepithelial infiltrates.
- Control (Type: None): patients received only artificial tears eyedrop

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous Dexamethasone on Duration of Hyperbaric Bupivacaine Spinal Anesthesia in Lower Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with American Society of Anesthesiologists score I-III,~* Patients undergoing lower abdominal surgery under hyperbaric bupivacaine spinal anesthesia~Exclusion Criteria:~* History of allergy to amide LAs or dexamethasone,~* Presence of a preexisting lower limb neurological deficit~* Chronic use of corticosteroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- normal saline group (NS) (Type: PLACEBO_COMPARATOR): patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia
- dexamethasone group (SD) (Type: ACTIVE_COMPARATOR): patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting BMD Z score \<-2 at the level of the femoral neck or of the lumbar column Regular transfusional regimen in order to mantain pre-transfusional Hb values \>9 g/dl.~Written informed consent by the patient~Exclusion Criteria:~Entravenous administration of bisphosphonates within the past 2 years~Administration of di bisphosphonates per os, unless wash out as it follows:~1 year if \>8 weeks \<48 weeks 6 months if \> 2 weeks and \<8 weeks Hypoparathyroidism Thalassemia Intermedia if not regularly transfused Pregnancy and breast feeding Impaired renal function (creat. \> 1.5 mg/dl) Neoplastic disease Patients with mean levels of alanine aminotransferase ALT \> 300 U/l and patients with variations of AST or AST of 300% within the year before randomization. (At least 4 misurations over 12 months) Systemic cardiovascular, renal, hepatic disease etc. which would prevent the patient from undergoing study treatment Known hypersensibility to bisphosphonates. History of non compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neridronato (Type: EXPERIMENTAL): Thalassemia Major or Severe Thalassemia Intermedia
- Placebo (Type: NO_INTERVENTION): Thalassemia Major or Severe Thalassemia Intermedia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Experimental Siblings with MELAS (A3243G) syndrome~* 17-23 years~* Followed Neurometabolic Clinic at the Hospital for Sick Children will be studied.~* Normal electrolytes, glucose, renal and liver functions \& no history of gastrointestinal, respiratory or cardiac problems.~Controls~-Aged 17-23- Sex matched to the MELAS subjects~Exclusion Criteria:~Controls~* Experience migraines~* Have a metabolic disorder~* Taking medications predisposing to lactic acidosis or vasodilatation~* Neuromuscular/neurologic condition~* Cardiac or pulmonary disease~* Visual abnormalities~* Hypertension, anemia and prothrombotic state. Control subjects~* Contraindication for MRI (pacemaker, ocular metal, claustrophobia, tattoos) will be excluded from the study.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- MELAS Patients (Type: EXPERIMENTAL): Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
- Control Group (Type: NO_INTERVENTION): Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects will be as follows:~  1. 4 weeks to 17 years of age,~ 2. fulfill the American Heart Association case definition for complete or incomplete KD,~ 3. have had fever (T ≥38°C) for 3 to 10 days prior to initial IVIG treatment,~ 4. have fever (T ≥38°C orally or rectally) between 36 hours and 7 days after end of the first IVIG infusion without other likely cause~Exclusion Criteria:~1. Patient treated with infliximab or steroids for present illness (pts who received oral steroids as outpatients prior to KD diagnosis but who otherwise qualify for the study will not be excluded)~2. Known prior infection with tuberculosis, coccidiomycosis, or histoplasmosis.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- IVIG (Type: ACTIVE_COMPARATOR): Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
- Infliximab (Type: ACTIVE_COMPARATOR): Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a New Technique to Improve the Symptoms of Orofacial Discomfort in Patients With Peripheral Facial Paralysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with PFP over six months of treatment~* indentations~* carrier fixed partial dentures and removable drives and/or dental implants~* palsy classified as Grade III according to House and Brackmann scale~Exclusion Criteria:~* patients who already had other diseases in the region of the jaws before facial paralysis~* is toothless from installing, using or not dentures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Visual Analog Scale (VAS) (Type: PLACEBO_COMPARATOR): Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~* VAS and dental cleaning at the first query.~* VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment).
- Occlusal adjustment (Type: EXPERIMENTAL): In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 70 years of age.~* Cancer of the colon or rectum.~* Metastatic disease diagnosed ≤ 6 months before enrollment.~* ≥ 1 measurable metastatic lesion.~Exclusion Criteria:~* Adjuvant anti-vascular endothelial growth factor (VEGF) treatment.~* Prior chemotherapeutic treatment for metastatic colorectal cancer.~* Past or current history of other malignancies (with the exception of basal and squamous cell cancer of the skin, or in situ cancer of the cervix).~* Clinically significant cardiovascular disease.~* Current or recent daily use of aspirin (\> 325 mg/day) or other non-steroidal anti-inflammatory drug (NSAID), or full dose anticoagulants.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + capecitabine (Type: EXPERIMENTAL): Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
- Capecitabine (Type: ACTIVE_COMPARATOR): Participants received capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of narcolepsy with or without cataplexy~* patients need to free of or discontinue psychostimulant medications for at least 14 days,~* patients with severe cataplexy are permitted to remain on their anticataplectic medications at stable doses~* patients must have adequate support to comply with the entire study requirements~Exclusion Criteria:~* Other conditions than Narcolepsy that can be considered as the primary causes of excessive daytime sleepiness~* Patients who are unable or unwilling to temporarily discontinue any no-authorized drugs or substances~* Psychiatric and neurological disorders such as psychosis or dementia, bipolar illness, severe anxiety, clinical depression, history of seizure disorder or other problem that in the investigator's opinion would preclude the patient's participation~* Current or recent history of a substance abuse or dependence disorder including alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BF2.649 (Type: EXPERIMENTAL): None
- Modafinil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 6-12 weeks and a major grade of HG clinical severity defined as follows:~* a PUQE score index ≥ 13 associated to one or more of the following conditions:~* weight loss \> 5% of pregravidic weight,~* electrolyte disturbances,~* dehydration,~* duration of symptoms \> 10 days ,~* inadequate food and drink intake~Exclusion Criteria:~* Language barrier.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clonidine first - placebo second (Type: OTHER): in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
- placebo first - clonidine second (Type: OTHER): in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30 to 75 years old~* In good health~* Has static and dynamic lateral canthal wrinkles (crow's feet)~* Has the willingness and the ability to understand and provide informed consent and communicate with the investigator~Exclusion Criteria:~* Pregnant or lactating~* Has received the following treatments:~  * botulinum toxin injections in the past 6 months~ * ablative laser procedure in the past 6 months~ * radiofrequency device treatment in the past 6 months~ * ultrasound device treatment in the past 6 months~ * medium to deep chemical peel in the past 6 months~ * temporary soft tissue augmentation material in the past year~ * semi-permanent soft tissue augmentation material in the past 2 years~ * permanent soft tissue augmentation material~* Is planning to receive within the next 3 months, any cosmetic procedure (such as any chemical peels, botulinum toxin injections, ablative or non-ablative laser procedures, filler injections, radiofrequency procedures, dermabrasion, ultrasound and face lifting procedures)~* Has an active infection on their face (excluding mild acne~* Has a history of neuromuscular disorders~* Has an allergy to albumin~* Has an allergy to Aquaphor AND petroleum jelly~* Has a history of bleeding disorders~* Is unable to understand the protocol or to give informed consent~* Has a mental illness

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum Toxin (Type: ACTIVE_COMPARATOR): The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
- Chemical Peel Only (Type: ACTIVE_COMPARATOR): After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete